MolProbity Ramachandran analysis

MolProbity Ramachandran analysis
1MCW, model 1
General case
180
W 58 SER
MM 204
170SER
LYS
M W
105142
THR
ASP
Psi
W 202 GLU
W 172 SER
W 147 ALA
W 95 SER
M 34 TYR
W M32 SER
9 SER
W 106
W LYS
2MSER
W67204
SERSER
M 169 SER
W 215 CYS W M
133165
LYSTHR
W 136 LEU
M 96 SER
M 47 LYS
W W87 99
ASP
WPHE
132 ASN
W 3 ALA
M
W 147
114 ALA
LYS
M 161 ALA
W 205 THR
W 83 ASP
M 63 ARG
W 54 THR
W 160 GLU
Isoleucine and valine
180
M 119 VAL
M 50 ILE
W 35 ILE
W 10 VAL
Psi
W 109 VAL
M 106 LYS
W 97 ALA
M 52 GLU
0
W 52 ALAW 173 ASN
M M19382ARG
ALA
0
M 44 LYS
M 29 VAL
M 42MALA
214 GLU
W 131 ALA
GLU
M M
126
M187
SER
127
GLU
W 9 SER
M M 2173
SERASN
M 174 ASN W 103 SER
W 28 ASP
M 3 ALA
M 171 GLNW 26 THR
W 27 SER
W 53
M VAL
53 VAL
M 215 CYS
W 135 THR
W 80 LEU
-180
-180
W 213 THR
M 4 LEU
0
Phi
Pre-proline
180
-180
180
W 81 LEU
W 210 VAL
-180
0
Phi
180
Glycine
180
M 45 ALA
Psi
Psi
0
0
W 203 GLY
M 15 GLY
M 162 GLY
M 31 GLY
W 144 TYR
W 185 THR
W 13 SER
W 211 ALA
-180
-180
-180
0
Phi
180
Trans proline
180
M
W 158
168PRO
PRO
0
Phi
180
Phi
180
Cis proline
180
W 124 PRO M 57 PRO
W 46 PRO
Psi
-180
Psi
M 212 PRO
W 42 PRO
0
0
W 186 PRO
W 82 PRO
W 145 PRO
W 14 PRO
W 212 PRO
M 46 PRO
W 123 PRO
W 113 PRO
-180
-180
-180
60.5% (259/428) of all residues were in favored (98%) regions.
77.1% (330/428) of all residues were in allowed (>99.8%) regions.
There
W
W
W
W
W
W
W
W
W
W
W
W
W
W
W
W
W
W
W
W
W
W
W
W
W
W
W
W
W
W
W
W
W
W
W
W
W
W
W
W
W
W
W
W
W
W
W
were 98 outliers (phi, psi):
2 SER (123.7, 160.0)
3 ALA (129.7, 79.4)
9 SER (129.7, -77.6)
10 VAL (65.0, 107.6)
13 SER (-120.7, -102.1)
14 PRO (-135.4, -100.2)
26 THR (-29.2, -111.6)
27 SER (24.2, -121.9)
28 ASP (-40.7, -97.2)
32 SER (124.8, 169.1)
35 ILE (141.8, 141.6)
42 PRO (12.3, 54.0)
46 PRO (-35.1, 165.5)
52 ALA (123.3, -7.4)
53 VAL (117.6, -104.2)
54 THR (-58.0, 19.0)
58 SER (-29.4, 144.5)
80 LEU (-58.4, -172.6)
81 LEU (165.3, 170.5)
82 PRO (-70.3, -63.3)
83 ASP (-59.0, 38.0)
87 ASP (130.2, 100.2)
95 SER (-39.3, 59.0)
97 ALA (176.2, 20.7)
99 PHE (143.2, 97.2)
103 SER (53.2, -87.1)
106 LYS (103.6, 162.7)
109 VAL (175.1, 65.0)
113 PRO (-46.4, -137.6)
114 LYS (164.0, 73.9)
123 PRO (-79.5, -123.8)
124 PRO (-116.8, 174.5)
131 ALA (120.5, -65.7)
132 ASN (170.5, 92.9)
133 LYS (155.7, 135.1)
135 THR (125.9, -157.7)
136 LEU (164.4, 129.9)
142 ASP (-7.6, 116.6)
144 TYR (-134.3, -47.5)
145 PRO (-81.8, -83.3)
147 ALA (-175.6, 66.9)
160 GLU (-171.0, 22.0)
168 PRO (-53.7, 97.2)
172 SER (-18.2, 79.5)
173 ASN (177.0, -4.9)
185 THR (123.1, -76.8)
186 PRO (-156.8, -41.3)
W
W
W
W
W
W
W
W
W
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
0
Phi
180
-180
0
202 GLU (9.1, 91.4)
203 GLY (37.2, 90.5)
204 SER (159.9, 159.0)
205 THR (154.1, 65.9)
210 VAL (160.1, -177.3)
211 ALA (-137.1, -164.6)
212 PRO (-112.7, -107.1)
213 THR (118.1, -175.2)
215 CYS (88.8, 139.1)
2 SER (80.8, -78.4)
3 ALA (161.4, -103.5)
4 LEU (161.6, -175.2)
9 SER (138.0, 166.9)
15 GLY (63.0, 81.4)
29 VAL (-30.7, -55.0)
31 GLY (-158.4, -24.8)
34 TYR (-172.9, 47.7)
42 ALA (120.7, -55.0)
44 LYS (169.7, -36.9)
45 ALA (119.3, 122.0)
46 PRO (-22.2, -98.8)
47 LYS (85.3, 101.9)
50 ILE (73.3, 133.6)
52 GLU (45.0, 9.3)
53 VAL (140.9, -108.6)
57 PRO (-50.9, 172.4)
63 ARG (-58.2, 30.9)
67 SER (147.9, 154.6)
82 ALA (107.1, -30.9)
96 SER (168.7, 115.0)
105 THR (-20.3, 116.0)
106 LYS (110.9, 32.0)
119 VAL (-36.0, 159.2)
126 SER (-46.0, -76.9)
127 GLU (-23.4, -76.5)
147 ALA (162.0, 77.3)
158 PRO (-57.0, 98.3)
161 ALA (82.5, 66.1)
162 GLY (-174.3, 22.0)
165 THR (170.3, 136.6)
169 SER (173.7, 142.3)
170 LYS (1.0, 129.4)
171 GLN (-85.4, -115.6)
173 ASN (90.6, -73.2)
174 ASN (-13.5, -85.9)
187 GLU (-32.9, -75.8)
193 ARG (96.3, -29.8)
204 SER (-5.6, 134.2)
212 PRO (-59.3, 76.1)
214 GLU (147.9, -58.9)
215 CYS (140.5, -146.7)
http://kinemage.biochem.duke.edu
Lovell, Davis, et al. Proteins 50:437 (2003)